Quick Takeaways
- BB BIOTECH AG filed SCHEDULE 13G/A for Black Diamond Therapeutics, Inc. Common Stock (BDTX).
- Disclosed ownership: 4.8%.
- Date of event: 19 Mar 2025.
BB BIOTECH AG - 19 Mar 2025 SCHEDULE 13G/A Report for Black Diamond Therapeutics, Inc. Common Stock (BDTX)
- Filing Manager
- BB BIOTECH AG
- Reporting Manager
- BB Biotech AG
- Symbol
- BDTX
- Shares outstanding
- 56,948,896 shares
- Disclosed Ownership
- 2,733,547 shares
- Ownership
- 4.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 21 Mar 2025, 13:01:32 UTC
- Date of event
- 19 Mar 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BB BIOTECH AG disclosed 4.8% ownership in Black Diamond Therapeutics, Inc. Common Stock (BDTX) on 19 Mar 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 21 Mar 2025, 13:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BB Biotech AG | 4.8% | 2,733,547 | 0 | 2,733,547 | /s/ Martin Gubler | Martin Gubler/Signatory Authority | |
| Biotech Growth N.V. | 4.8% | 2,733,547 | 0 | 2,733,547 | /s/ Jan Bootsma | Jan Bootsma/Signatory Authority |